This study looks at how well a new medicine, called **JNJ-79635322**, works compared to another medicine for people with **multiple myeloma**. Multiple myeloma is a cancer of the bone marrow, where blood cells are made. The study is for those whose disease has returned or didn't respond well to treatment.
To join, participants must have been diagnosed with multiple myeloma and tried at least three treatments before. They should not have serious infections or allergies to study medicines. Also, they shouldn't have had major surgeries recently or plan any during the study.
Key points:
- Study length and number of visits will be explained by the study team.
- You must stop other cancer treatments to join this study.
- Potential risks and benefits will be discussed with you before starting.
How understandable was the trial content above?
Hard to understand
Easy to understand